PMID: 48894Jun 7, 1975Paper

Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction

Lancet
R W CampbellD G Julian

Abstract

The incidence of ventricular arrhythmias after myocardial infarction has been compared in a controlled study of procainamide, mexiletine, and placebo. Sixty male patients who has sustained a myocardial infarction and had received lignocaine for ventricular tachycardia or ventricular ectopic beats which were R-on-T, multiform, or close-coupled took part. The efficacy of the drugs was evaluated by continuous 24-hour recordings of the electrocardiogram on the 4th and 10th days after admission to the study. Procainamide was given as 500 mg. 4-hourly and mexiletine as 250 mg. 8-hourly with corresponding placebo regimens for 12 days. 77% of patients receiving placebo showed serious ventricular rhythm disorders compared with 33% receiving antiarrhythmic therapy (p smaller than 0.05). Although only 35% of patients receiving procainamide achieved accepted therapeutic plasma concentrations compared with 95% of those receiving mexiletine, both drugs were equally effective antiarrhythmically. The only major adverse effect of therapy noted was development of a positive antinuclear factor in a procainamide-treated patient. These results demonstrate the efficacy of oral antiarrhythmic agents in the management of ventricular arrhythmias after ...Continue Reading

References

Jul 1, 1971·Circulation·B Lown, M Wolf
Jun 1, 1973·Circulation·B D KosowskyR F Ritchie
Aug 25, 1973·Lancet·N P CampbellJ F Pantridge
Sep 1, 1967·The American Journal of Cardiology·A M FakhroB Lown
Jul 10, 1969·The New England Journal of Medicine·S E BlomgrenJ H Vaughan
Dec 1, 1969·Arthritis and Rheumatism·J MolinaG J Friou
Dec 1, 1973·European Journal of Clinical Pharmacology·E Karlsson
May 1, 1969·Progress in Cardiovascular Diseases·J T Bigger, R H Heissenbuttel
Dec 4, 1969·The New England Journal of Medicine·J Koch-WeserR W DeSanctis
Aug 3, 1972·The New England Journal of Medicine·J Koch-Weser
Aug 1, 1969·American Heart Journal·R I Wang, G Schuller
Jan 1, 1957·Circulation·B B BRODIEJ M STEELE
Apr 30, 1964·The New England Journal of Medicine·S PELL, C A D ALONZO
Jul 1, 1951·Circulation·H J KAYDENB B BRODIE

❮ Previous
Next ❯

Citations

May 1, 1990·Clinical Cardiology·A S ManolisN A Estes
Nov 1, 1991·Journal of Clinical Pharmacology·H FruminN Kerin
Jun 19, 1978·European Journal of Clinical Pharmacology·G Koch, B Lindström
Jul 1, 1981·The American Journal of Cardiology·M SamiR F DeBusk
Aug 1, 1978·British Journal of Clinical Pharmacology·N P CampbellR G Shanks
Oct 1, 1977·British Heart Journal·G I FiddlerM J Godman
Jul 1, 1978·British Heart Journal·N P CampbellA A Adgey
Aug 1, 1978·British Heart Journal·T G Pickering, L Goulding
Feb 1, 1979·British Heart Journal·N P CampbellJ F Pantridge
Jan 1, 1980·Progress in Cardiovascular Diseases·B N SinghC Y Chew
Mar 1, 1980·The American Journal of Cardiology·J J HegerD P Zipes
Apr 12, 2016·Chemical Research in Toxicology·Richard LonsdaleAdrian J Mulholland
Feb 1, 1990·Chest·S N SteenT R MacGregor
Jan 1, 1981·The American Journal of Cardiology·J P DiMarcoJ N Ruskin
Oct 7, 2016·SAGE Open Medicine·Scott D NeiChristopher J McLeod
Jan 1, 1987·The New England Journal of Medicine·R W Campbell
May 1, 1977·The Journal of Pharmacy and Pharmacology·A H Beckett, E C Chidomere
May 1, 1976·Postgraduate Medicine·J Koch-Weser
Sep 1, 1982·British Journal of Clinical Pharmacology·D El AllafA Dresse
Apr 1, 1986·Drug Intelligence & Clinical Pharmacy·B J Schrader, J L Bauman
Jan 1, 1986·Pharmacotherapy·P E Fenster, K A Comess
Jan 10, 2003·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·L LabbéJ Turgeon
Jan 1, 1979·Acta Medica Scandinavica·L StavenowB W Johansson
Nov 1, 1977·Progress in Cardiovascular Diseases·D C HarrisonR A Winkle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.